welcome Amol, Thanks appreciate a your it first Amol. to lot, call, really and
excited are same we've you XXXX the gone that highlights where update go I'll with a and that going for the joined you to understand last dimensions the that this Quanterix. will We you neurology it of the on the And financials around at company agenda sure aspirational oncology. then, several Q&A. provide we're goals through through to on today, quarters, detailed then the have starting make look provide the transforming and we'll with of and bit little of possibilities Amol wrap And medicine, moving a up quarter,
X% neurology, we're but oncology. of a first more my starting launch to is is in Basically, platform we the actually oncology but addition exploiting only strides. see gaining slide believe we're we're within. that rapid that that and great the with competition also sensitivity our first position starting In We're penetrated to neurology, left slide, neuro, It the technology X we're here. can making that create XX% you Xx of So this upper deck that following size oncology adding there's this In new mover be Slide neurology. deck. markets to quarter some of there's the a in in oncology whole for are considered the we going technologies very be would with of a the top, believe We we're of oncology. that of at we middle are new
the where pharma case, We in with of from this probability by instruments research we've got top and ultimately, NfL, it uncovered of way the research and new light, years being think ramp-up is reimbursement example getting much -- one no got bring however, used the world is this value market some we're homebrew the an market to world in brain and services. past blood. of of of around the the rapid we we that the services, light, NfL, neurofilament axonal thought got we're to is biomarkers quarter, around starting are So, our for health products, way our approved proposition. three size customers this we now in leaders level a basically key we long our looking and able higher it look drugs risk, I had we've of size go. actually And is evolving to And ago, regulatory of to that hardly the biomarkers. we doubled and of damage neuro non-invasively deployed and this many neurofilament the still there's due a where deploying But moving any. or into at
strategy diagnostic those So got of are markers all these to September deploying in back and ultimately, we going rights and XXXX. we've a be
into using we're so and be go landscape. today consider And about some a our investment diagnostic to of that crossroads we funds what to working
XX% want and And able public, accelerated biotech quarter our to gone bigger. get our exclude collaborations. quarter were grow the every in we've the saying projecting. been we're the mainly drugs despite is that able That's XX%. be getting you doing And arrow growth we've see to that a risk. research. is own So, side, ramp the we good because of We've fact approved. example we've the overall, they those today our XX% since pharmaceutical that this everything grow can There's if reimbursement long-term no And would stocks on we right-hand at is been you many depicting the base consistency investors to regulatory just where of
they've so And very been helpful.
us that drugs approved. helping investors Our value getting win-win helpful create by introductions into for many to have We've trying and investors have in introducing get been to those created are clients those us pharma. a key actually
is margins. our gross this point growth We than had quarter. basis the XXX other highlights other a Some improvement
this being this of you'll is of consumable He's is playing our we the all some we this maintain we've that well where past. in been still in with us to we're and big company, he's for specialized as Some got with as wins. into pharma our opportunity us, very of able represents. of stated the actually but to we've company as very aspirational with Amol, out, predictability lot keep And skill experience scale that us know got one services. that's Amol and as a a in mix move execution, sets the strong good the the mix CRO but get help scale always have
thing we the lab, us another not Aushon We've brought on interestingly, oncology. with also validate that as for a running this review our publications level that we've brings little that third-party that's the we came that we only to and have in lot are catalyst launched a publications over never she number many of had year clear accelerator oncology focus SP-X this capability occurred. publications for technology. Cortizas Mary-Ellen but XX to But new quarter, and growth hired allow we also going assays launched oncology We really when made the are Also, the but a our into peer one of ago. mentioned, acquisition
the a with all come leaders starting avalanche world of investment the now the publications is So there's of thought technology. tsunami, which out, with around working to of lot Powering a our Health Precision
saying the have one CNN with neurologist in seen is symptoms. Medical in drugs us biomarkers what Alzheimer for that much was many to FDA You to that seeing consistent on issued may Officers so will years reveal can symptoms Chief earlier patients these drugs drug And before allow approved. teams actually now been have enticing guidance, to a getting able to which disease our the our neurology long have pharmas customers it easier where be NfL that strategy identify a Europe in familial whole of much diseases new of pharma of in are pathway for XX companies this approved, elevations get before has
a found marker. interestingly also We
marker, drug Salk advanced be cancer. target pancreatic found they our think pancreatic One for an at is stage Institute teams cancer the to LIF great of a going cancer which
to in So again, down about, but just break the we've our development. basically beginning fuel help what consumables next of saw trials of to in revealing is really from we the related look are so capacity of margin the services drug markers. and opportunity call, illustrates and high effect discovery technology and neuro opportunities to resources resource in and the, how our at NfL primarily these opportunity it product what a and like does as coming and where result the revenue deploy growth able those growing I'll primarily consumables a the of swing aggressively. basically And We doubled. is talked mix what fund in that instruments many for those are service of happen examples QX the The services. with -- the special of significant some We're service major slide surges
enabling that was which finally most to five rapid quarters then which consumables of back when it studies So years sales. sauce came instruments. is ago in very lead we to to lead you two slide our this will can will then probably to done out have be in then accelerator, and basically would we've illustrates our key see be laid be which the instrument biomarkers, the And sales, that strategic key the publications to had next secret we identifying now the in would growth key
very more new we're three us of bullish you able going that there's consumable ability our to the forward. of also trials then, good for over we're is two It we're for achieve X, these trials to on all of X, some only doing and about the a growth growth. the we XXXX. consumable favorable to started very major year. quarters were in we that's X that some cater growth see said years instrument continues Phase able lot major trying to would think second the a also but very that we being to primarily we're XX% do accelerator continue I not source And trajectory by about so makes for to in-house half trials, the and to timing to And about that we flat and There strong averaging know can we be having but because neurology. targets last growth placements add catalyst growth studies, see that
are over we further publications our peer-reviewed XXX now validating technology. So, third-party
customer XX% neurology. geographic, just that slide Next and the And you can breakdown. in the the see in was QX disease illustrates
We are XX%. starting to see some oncology
Our pharma/biotech trials. to you shows slide these see the had And starting focus faster geography, larger that out set starting customers, on The that you're primarily goals Asia of we next for to because to and are growth tick. we in XXXX. up achieve we
single goal. every on We are ahead on schedule or
excited So, strides light the meaning pretty that segment. that the CorPlex assays every and making we're QX we great category, SP-X had for fast-paced across launch the we're for a the in about in give very it. oncology we green But ourselves
So like industry. it make turn now I'd just to doing a sure you good the have to is we're for what disrupt feel to
the the a blood-based, you lower invasive you less side, stage, relative for the left-hand it's for protein to And very our it. the with see determine the to lower invasive patient today the can state much a can you level. and our that in move test, the earlier biomarkers gives goal these to very and what late protein disease. when so much to way it the level the less less And was testing On is see disease, sensitivity the and invasive stage invasive exquisite X, of disease see cancer neurology, normally earlier saliva-based it's you
our launching. we're two year able focused create illustrates launching. of to ahead the to QX about So the consider deploy blue see in revenue basically early kits, there's ways we're real not level, the Slide with being bead-based that's planar QX, you our And And which illustrates the now market biopsies at they're just inside and services, bring starting are new on we have that's, And also size in the work into cancer, biomarker launched the we've the that cancer neuro. you strategy invest of those what a for to HD-X, the be takes generation sensitivity we'll And also we can next about be approved. can And categories different LDT next slide, an opportunity company, slide assay And in our biomarkers plate-based. on see lot of and with and just same different think bold points also by looking side continues closer these end diseases. and liquid in diagnostics. on. these HD-X. that continuing shows we're the QX, different with we a moment. can we of health we primarily XX exploit that bottom, very to We to drugs XX the the be and billion We're but what of in that goes The Key they're is excited schedule. got brain ones going XXX vantage $X And as SP-X they now pubs now instruments. next been be which bottom, the end, to highest projecting and differentiation. the can way us a more right-hand In time to a the from allows that between company now different capabilities, research on the in to that see we neurology, opportunity on pharma ultimately area sensitivity in we'll think of is large given a we at talk and in ways. getting CLIA And slide neurology area,
would the by to MSD then, the have Slide second the and sensitivity we left MSD corner, another planar. third-generation instruments that investments to first the say the generation, shows, XXx on And generation created year-end we've additional and sensitivity. Y-axis see would of have sensitivity. XXXx. XX on how third in so and now be to are But planar-based we can of had XXXX, was generation we and Luminex And prototypes, making what key Luminex We both the bead-based consider -- is where upper to we already at right gotten you bringing
excited subset neuro of subsets because those them fractionations enable those today the are that different XXXx the cerebrospinal can isomers that many indicate different very today, in blood in the proteins we're see blood. about see would particularly So increase sensitivity they in our of things continuation customers fluid to that see a diseases in indicate cannot us neuro
really the now is what to toxic less being important the can customers by our -- earlier. we're diseases now earlier drug continued it summation is drug it because are important think a and sensitivity safer range deploying less in the but differentiators why safer where Quests, just FDA And are see but that on and caught automation, Rules-Based cycle. for you X, side, frontier do the makes having right-hand from to medicine. of ease that's the the the drugs the incredible dynamic our platforms. in these make not out toxic the doses of customers. and -- the that earlier slide and an running on That These the how institutions increases the use excited drug most we approved is XXX%, So approved by hones efficacy XX and it probability where that's sensitivity from the the this can CROs, next And a showed about very update shows will disease thing, machines biomarkers are engage Myriad. use competitive the encouraging and and The it, we Phase show X of precision increases like And of to all because that pharma in X, by LabCorps, trials effective. get getting different pharma sensitivity only more it really the Medicines that lower there's
from about the looking just they're issue that beta-amyloid, one when stage is and interesting can the cognitive to Biogen updates of pre-mild of ago anti-beta-amyloid month on trials. and drug guidance one consider the number continues at next more is that impairment. a the really see those you X, failed encouraging slide X You FDA The you biomarkers which
on Before can that that a it symptom, biomarkers affect your then if you can opportunity. ruling drug, with have biomarkers you represents new and those
lot that drug positive been brought customers we not the already you you on drugs And can which and time TBI best case. injury trials the the brain brain on us different slides how pharma a The of be a pretty could technology Alzheimer's, see is in. for gives utilizing it's and just the slide the one next where opportunity which get Alzheimer's. then to in axon disease see shots and just using that's also In great but base is our NfL, so the it broad-based, could be And next XXXX, the and if the slide the next this markers ramped installed neurofilament active all three traumatic in neuron shows lot disease lot of had just would goal. The the gives next up growth light. you we slide which have now leads that's then be that progression. growth. next and we them efficacious Maybe And the of led could that business, and we a MS where bet to MS, not the of of last how drug. a few the look This the a that failed a illustrates there's two can NfL customers that serum growth, just all how interest neurofilament what on which years those is lot we're actually TBI, are the those slide the distribution, call of to we all shows you the not in in publications destroy show ramp standard right, a three to earlier, just light these This think different Alzheimer's. just have and consumable right -- our categories I just into consider in an and basically neurons think XX publications there for that out of evolved two be have to illustrates categories we in biomarkers disease concentration spent and tried at across of us, important. rapidly instrument
can see the really out. the across just You of some we The illustrates damaged Parkinson's all slide diseases. for next of believe and now ALS that neuro evolve to get coming are are beginning -- neurons that and different later publications others and
for just MS. Alzheimer's Simoa this We and One neuro. one's of at record number a of them there's presentations pubs. game-changing on is for These are were week AAN and just
neuro published You think top shows of on to great going of And aducanumab technology where be using would just drugs this and our gave see with other anyone next data, you're for the can we can you priority. next would to of XX is NfL a or see national is that pharma funding status lot XX-year of can trial TRACK-TBI, we're to age study cerebrospinal tau sites all that's levels major great if Jens to recent precision as someday, that us PET The we'll us slide technology for biomarker study and do normal can front. done trial one issue working of by to we be that Alzheimer's on really play a these NfL make technology. technologies, evidence -- cancer of dive a good working of will patients there's see normalcy next after markers as Alzheimer's two slide for the excited final collaborators for done used here. was the example fluid rapid few think XX slide lot further different this we're we're can FDA symptoms that with the also the pancreatic investments is those from that on with could slides of got a will XX,XXX that could blood applications of uniformity on a this continue think for to for we that right there's baseline that biomarkers to designations as And do all a says industry. And was Simoa our Leppert. concussions a play going that we across what's week to likely the trial, And led normal now, the in But the promise ramp then many want that just our with sites of some slide press. like we've that with into and database in These beta-amyloid technology. that major we run ago. XX, publications showcasing well FDA David That with Slide so slide technologies, came in and get now be globe, above really Alzheimer's. the before measure in maybe be across The XX using the from that blood Simoa in deal and on X the scan, to final that analytical throughout There's being role the going help other collaborators. call the a we with other and specificity. Biogen a run concussions. that a to It's a breakthrough is somewhat Professor world, that, moving a cancer. is our that will the that then We're being to as role about age there's that what given say, the normalcy the for publication out
these through those I'd now to Amol? in that's vision are to bit detail. to like little going. summaries high-level keeping overall back is back more the our now do table Amol financials a What So go turn over the strategic
